- Bayer – Global Home
At Bayer, innovations in health and agriculture are at the core of what we do We develop solutions that improve lives and protect the planet
- Health for all, Hunger for none | Bayer United States
It’s not only our mission, it’s what fuels each and every one of us, every single day At Bayer, our commitment is to better the lives of all Americans – we’re finding groundbreaking solutions that help put food on our tables and offer innovations in self-care and medicine for all Americans so they can live better lives Video: Through the power of science, we strive for a world where
- Careers | Bayer USA | Bayer United States
A career with Bayer means you can put your passion into practice and make an impact
- Contact | Bayer Global
For Bayer as a global pharmaceutical company, pharmacovigilance takes center stage, beyond mere compliance with worldwide regulations To enable Bayer to provide up-to date safety information on Bayer products, your support is pivotal, whether you are a customer, patient or healthcare professional
- Bayer U. S. | Crop Science | Bayer United States
At Bayer, we work every day to grow America’s future We are passionate scientists, agronomists, field reps, supply chain specialists, and farmers (yes, we farm too) who are committed to strengthening the American farmer’s tool box
- Bayer in Radiology Official Site
Privacy Statement Conditions of use Sitemap California Transparency in Supply Chains Contact Us
- Bayer welcomes Solicitor General support for U. S. Supreme Court review
Leverkusen, December 2, 2025 – Bayer is pleased the Solicitor General supports U S Supreme Court review of the petition for a writ of certiorari in the Durnell case and agrees with the company’s arguments on preemption The company believes that the backing of the U S government will be important to the Court’s consideration of its petition The split among federal circuit courts in
- Bayer’s FXIa inhibitor Met Primary Efficacy and Safety Endpoints in . . .
Not intended for UK Media Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke PreventionOCEANIC-STROKE demonstrates superiority of asundexian with antiplatelet therapy, showing significant reduction in ischemic stroke risk, without increasing ISTH major bleeding rate, comp
|